- Home
- MNOV vs BTMD Comparison
MNOV vs BTMD Comparison
Compare MNOV & BTMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNOV | BTMD |
|---|---|---|
| Founded | 2000 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.9M | 64.4M |
| IPO Year | 2004 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MNOV | BTMD |
|---|---|---|
| Price | $1.40 | $1.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $7.50 | $2.25 |
| AVG Volume (30 Days) | 55.9K | ★ 302.1K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 722.22 |
| EPS | N/A | ★ 0.74 |
| Revenue | $2,360,807.00 | ★ $192,219,000.00 |
| Revenue This Year | N/A | $2.03 |
| Revenue Next Year | N/A | $6.58 |
| P/E Ratio | ★ N/A | $1.96 |
| Revenue Growth | ★ 194.15 | N/A |
| 52 Week Low | $1.13 | $1.27 |
| 52 Week High | $1.96 | $4.75 |
Technical Indicators
Market Signals| Indicator | MNOV | BTMD |
|---|---|---|
| Relative Strength Index (RSI) | 46.32 | 38.05 |
| Support Level | $1.21 | $1.35 |
| Resistance Level | $1.43 | $1.69 |
| Average True Range (ATR) | 0.06 | 0.14 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 24.25 | 39.76 |
Price Performance
Historical ComparisonAbout MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
About BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.